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Introduction
Clozapine, a second-generation antipsychotic, is considered 
the antipsychotic of choice for patients with schizophrenia or 
schizoaffective disorder whose symptoms are partially or fully resistant 
to treatment with other antipsychotic drugs or accompanied by 
persistent suicidal or self-injurious behaviour [1]. However, its use 
is limited by the risk of haemotological side effects and the need for 
regular monitoring of haemogram [2,3]. The most serious side effect 
of clozapine is agranulocytosis with two phenotypes on a spectrum of 
severity [4], starting from benign neutropenia (cumulative incidence 
2,7% during the first year of use) with absolute neutrophil count (ANC) 
≤ 1,5×103/µL to possibly fatal agranulocytosis with ANC ≤ 0.5×103/µL 
(cumulative incidence 0,8% at 1 year and 0,91% at 18 months) [1,5]. The 
risk of clozapine-induced agranulocytosis and neutropenia is highest in 
the first 6 months and higher in the initial 18 months after the onset of 
treatment [1,6].
The mechanism of clozapine-induced agranulocytosis has not 
been fully described. Neither clozapine nor its major stable metabolite, 
N-desmethylclozapine, at therapeutic drug concentrations have been 
found to be directly cytotoxic or interfere with the turnover of bone 
marrow precursor cells [4,7].
Significant and independent factors associated with clozapine-
related agranulocytosis are female sex, older age5, and use of 
concomitant medication [8].
Management of clozapine-induced agranulocytosis orders 
immediate discontinuation of the drug1. To prevent morbidity and 
mortality from infection, antibiotics should be instituted promptly 
for febrile neutropenia [1,5]. Colony-stimulating factor are also often 
used1 since their use may reduce the duration of agranulocytosis by 4 
to 5 days [5].
Case presentation
A 42-year-old Caucasian woman presented to the Emergency 
Department (ED) of our hospital with one-month fatigue. She also had 
a fever started 3 days before. For a dental abscess, she was receiving 
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amoxicillin/clavulanic acid 875/125 mg, paracetamol 1000 mg, and 
diclofenac 50 mg for the previous 4 days. 
There was no history of psychiatric disorders until 12 years ago 
when the patient had a postpartum depressive episode after the birth 
of her second daughter. The patient started antidepressive therapy 
with sertraline and completed it for 3 years, with progressive weaning 
until suspension. Four years later, she developed persistent delusion 
disorder (a highly systematic delusion with the consistency of the 
paranoid theme). The patient had been hospitalized the year before, 
due to the intensification of the delusional activity dynamism. She 
started antipsychotic therapy with paliperidone and olanzapine titrated 
to an effective dose without any repercussions on delusional activity. 
For that reason, refractory psychosis was assumed, and clozapine was 
instituted gradually up to 300 mg per day. The patient also started 
depot therapy with paliperidone palmitate 150 mg per month to ensure 
greater adherence to the therapeutic regimen. With clozapine titration, 
significant improvement in delusional ideation and greater affective 
distance from it was reported in the first months of treatment. 
At the ED, the patient was pale, febrile, and her blood pressure 
was 118/67 mmHg, while her pulse was 118 beats per minute 
and regular. Heart and breath sounds were normal. There was no 
hepatosplenomegaly, lymphadenopathy, abdominal tenderness, or 
mass. The patient had ulceration of the perianal region with exuberant 
inflammatory signs suggestive of candidiasis.
The main investigations of the patient showed, on blood samples, 
agranulocytosis (leukopenia 0,6×103/µL and severe neutropenia 
0,0×103/µL) and lymphopenia (0,6×103/µL) (Table 1). The hemoglobin 
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level was 12,2 g/dL and plaquette count 405×103/µL. The serum sodium 
was 132 mEq/L, serum potassium 3,2 mEq/L, alanine aminotransferase 
(ALT) 88,2 U/L, aspartate aminotransferase (AST) 38,9 U/L, gamma-
glutamyltransferase (γGT) 132,3 U/L, lactate dehydrogenase 158 U/L 
and C-reactive protein (CRP) was 334,96 mg/L. Chest X-ray and ECG 
were performed and both were normal. 
She was diagnosed as having drug-induced agranulocytosis with 
febrile neutropenia. Clozapine was immediately withdrawal and she 
was maintained on strict aseptic precautions and isolation procedures. 
Bone marrow aspiration revealed a dry tap. The patient started therapy 
with filgrastim, a granulocyte colony-stimulating factor (G-CSF), 
on day 1. Blood cultures were collected, and the patient started IV 
empirical antibiotic therapy with piperacillin/tazobactam 4,5 gr. She was 
admitted under the department of Hematology. To the initial regimen, 
fluconazole 100 mg was added for the management of candidiasis.
During hospitalization, further investigation was performed. 
Thyroid hormones were within normal limits. Serologic tests, hepatitis 
B, hepatitis C, anti-DNA, antinuclear, proteinase 3, antineutrophil 
cytoplasmic (PR3-ANCA and cANCA), perinuclear antineutrophil 
cytoplasmic antibodies (pANCA), and antineutrophil cytoplasmic 
antibodies against myeloperoxidase (MPO-ANCA), were negative. The 
blood cultures were also negative. 
On the third day of hospitalization, the patient maintained paranoid 
ideation that emerged during the interview, without significant 
psychotic distress. She had depressive mood and anxiety, configuring 
an adjustment disorder. Lorazepam 2,5 mg at bedtime was introduced 
and then increased to 3,5 mg. It was deferred the introduction of any 
other therapy until analytical improvement.
After the first course of antibiotic therapy, fever persisted. The 
patient collected two blood cultures and urine culture and started a new 
antibiotic therapy with meropenem 1 gr. Both cultures were negative.
On the eighth day, the patient was psychopathologically worst, with 
progression to depressive mood, emotional lability, initial insomnia, 
and polifragmented sleep with recurrent nighttime awakenings. 
The past spontaneous delusional activity did not emerge. Regarding 
insomnia, with a high impact on mood, she started zolpidem 10 mg 
at bedtime.
Despite antibiotic and antifungal therapy, the patient maintained 
fever and pain in the perianal region. Rectal examination was 
impossible to perform due to the patient’s intolerance. A perianal 
abscess was assumed, and the patient started another antibiotic 
therapy with vancomycin. Magnetic resonance was performed and 
showed concentric thickening of the low rectum wall, associated 
with adenopathies in the adjacent perirectal fat, findings suspected of 
neoplastic lesions (Figure 1). Adjacent to the posterior aspect of the 
anal sphincter complex, there were imaging changes compatible with 
an active inflammatory process, but without evidence of fistulous 
trajectories or suspicious collections. Colonoscopy was performed and 
showed, in the rectum at 8 cm from the anal margin, an area of mucosal 
retraction with a scarred aspect and pseudopolyps (Figure 2). Biopsies 
were performed and revealed nonspecific morphological changes.
During and after granulocyte treatment, her neutrophil and 
monocyte counts rose, and her clinical condition improved. Filgrastim 
was suspended on the twenty-third day and a myelogram was 
performed, showing granulocytic lineage. Flow cytometry performed 
revealed 2% of blast population with normal phenotype. Table 1 
demonstrates the course of the patient’s white blood count during and 
after granulocyte treatment. 
Figure 2. Colonoscopy showing mucosal retraction with a scarred aspect of the rectum
Figure 1. Magnetic resonance showing concentric thickening of the low rectum wall
The patient was discharged. She suspended zolpidem 10 mg 
and initiated flurazepam 15 mg, with follow-up by Psychiatry and 
Hematology. Taking into account the agranulocytosis, as well as the 
reduction of the dynamism of the delusional activity without functional 
repercussion, it was decided not to reintroduce any antipsychotic for 
now.
Discussion
We presented a case of clozapine-induced neutropenia and 
agranulocytosis in a patient with persistent delusion disorder treated 
with clozapine for 3 months.
Clozapine-induced agranulocytosis is a rare condition in 
comparison with other fatal complications of clozapine treatment (i.e., 
bowel obstruction, myocarditis) and it needs to be properly detected 
and addressed [7]. 
Clozapine can induce two clinically distinct types of agranulocytosis 
on a spectrum of severity, starting from benign neutropenia (cumulative 
incidence 2,7% during the first year of use) with an absolute neutrophil 
count (ANC) ≤ 1,5×103/µL to possibly fatal agranulocytosis with 
ANC ≤ 0.5×103/µL (cumulative incidence 0,8% at 1 year and 0,91% 
at 18 months) [1,5]. In the first type, when clozapine is discontinued, 
recovery is usually rapid (2-8 days) [9] but in the second type, as in 
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the present case, even if clozapine is discontinued, agranulocytosis 
generally lasts for 14-21 days [9].
The incidence of agranulocytosis is reversible in most cases 
once clozapine is withdrawn promptly. In our patient, immediate 
discontinuation of clozapine upon diagnosis and G-CSF introduction 
managed the increase in the neutrophil count and the improvement of 
the patient’s clinical presentation.
The pathophysiologic mechanisms that produce clozapine-induced 
agranulocytosis are not well understood. There is an age-related 
increase in the risk of 53% per decade [9]. The risk of neutropenia or 
agranulocytosis is not, however, dose related [9]. Furthermore, some 
authors have suggested an increased incidence in women [9].
The role of the physician is to carefully assess modifiable risk 
factors, focusing on drug-drug interactions and potential interactions 
associated with clozapine metabolism. The decision for treatment 
continuation in the case of clozapine-induced agranulocytosis should 
be made based on careful consideration of risk factors.
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Laboratory test Normal range Day 1 Day 3 Day 7 Day 12 Day 17 Day 23 Day 3 without filgrastim
White blood cell count 4,5-11,0 x 103/µL 0,5 0,9 1,7 1,2 1,4 51,0 67,5
Neutrophils 2,0-7,5 x 103/µL 0,0 0,0 0,0 0,2 0,2 42,8 57,7
Lymphocytes 1,5-4,0 x 103/µL 0,4 0,9 1,7 0,2 0,3 7,6 6,3
Monocytes 0,0-1,0 x 103/µL 0,0 0,0 0,0 0,7 0,8 0,2 0,3
Table 1. The course of the patient’s white blood cell count during and after granulocyte treatment
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